Mr Mark S Harris, OD in Akron, IN - Optometrist

Mr Mark S Harris, OD is a Optometrist based in Akron, Indiana. Mr Mark S Harris is licensed to practice in Indiana (license number 1927) and his current practice location is 100 W Rochester St, Akron, Indiana. He can be reached at his office (for appointments etc.) via phone at (574) 893-7050.

NPI number for Mr Mark S Harris is 1174594006 and his current mailing address is Po Box 640, Akron, Indiana. He does not participate in medicare program and thus does not accept medicare assignments. His NPI Number is 1174594006.

Contact Information

	Mr Mark S Harris, OD
	100 W Rochester St, Akron, IN 46910-9997
	(574) 893-7050
	(574) 893-7540

Healthcare Provider's Profile

Full Name	Mr Mark S Harris
Gender	Male
Speciality	Optometrist
Location	100 W Rochester St, Akron, Indiana
Accepts Medicare Assignments	Does not participate in Medicare Program. He may not accept medicare assignment.

NPI Data:

NPI Number: 1174594006
Provider Enumeration Date: 01/30/2006
Last Update Date: 01/26/2011

Medical Identifiers

Medical identifiers for Mr Mark S Harris such as npi, medicare ID, medicare PIN, medicaid, etc.

Identifier	Type	State	Issuer
1174594006	NPI	-	NPPES

Medical Taxonomies and Licenses

Taxonomy	Type	License (State)	Status
152W00000X	Optometrist	1927 (Indiana)	Primary

Medicare Part D Prescriber Enrollment

Any physician or other eligible professional who prescribes Part D drugs must either enroll in the Medicare program or opt out in order to prescribe drugs to their patients with Part D prescription drug benefit plans. Mr Mark S Harris is NOT enrolled with medicare and thus cannot prescribe medicare part D drugs to patients with medicare part D benefits.

Mailing Address and Practice Location

Mailing Address	Practice Location Address
Mr Mark S Harris, OD Po Box 640, Akron, IN 46910-0640 Ph: (574) 893-7050	Mr Mark S Harris, OD 100 W Rochester St, Akron, IN 46910-9997 Ph: (574) 893-7050

News Archive

Insilico Medicine launches new system for COVID-19 basic and clinical research

Today Insilico Medicine, a global leader in artificial intelligence for drug discovery and development, announced the launch of a new system for COVID-19 basic and clinical research.

Penn researchers tag CAR T cells with imaging markers to monitor cancer therapy

With CAR T cell therapy, a patient's own immune cells are genetically modified and inserted back into the body to find and kill cancer. This form of immunotherapy has already revolutionized some cancer treatments, but once the CAR T cells are inside a patient, where do they go? How do doctors know that they have successfully reached their target and that they are continuing to fight disease weeks, months, or even years later?

Preliminary top-line results from Hematide Phase 3 program for anemia in chronic renal failure patients

Affymax, Inc. and Takeda Global Research & Development Center, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, today announced preliminary top-line results from the Phase 3 clinical program for the investigational drug, Hematide™/peginesatide, for the treatment of anemia in chronic renal failure patients.

Cancer-causing mutation also promotes inflammation

Analyses of cell signals provide insight into the origin of severe inflammatory symptoms that appear in various types of blood cancer and point to possible therapeutic approaches: In around one-fourth of patients suffering from juvenile myelomonocytic leukemia, there is evidence of mutations in the so-called KRAS gene in the leukemia cells.

NIPH study finds NDMA as one of the most carcinogenic compounds formed during CO2 capture

CO2 capture by means of amines is considered to be the most appropriate method to quickly begin with CO2 removal. During this capture process, some of the amines escaping the recycling process will be emitted into the air and will also form other compounds such as nitrosamines and nitramines.

Mr Mark S Harris, OD - Optometrist in Akron, IN